Heart disease drug is disappointing
Abstract: The study found that a abciximab called on the stability of the anticoagulant heart attack and reduce its mortality effect has been disappointing.
Amsterdam, The Netherlands (AP) study found, the doctor can help quickly stabilize heart attack, reduce the mortality or morbidity an anticoagulant is disappointing. This can be called the drug abciximab in patients with heart artery expansion of interventional treatment, such as angioplasty, to prevent condensation blood cell adhesion to save lives, so that these operations more safe and effective. Its people impressed by the results, which researchers hope it can be improved non-surgical treatment the prognosis of the patients. But researchers found that it did not have the slightest effect.
European Heart Association in a meeting held on Monday announced the discovery. In a 7800 case of a heart attack caused by severe chest pain patients in the international study, all patients had mild anticoagulant rapidly taking the role of aspirin and heparin, as a basis for treatment. These patients the risk of a heart attack is high because they have not been completely blocked artery embolization flow.
In addition to aspirin and blood dilution, half of patients in 24 or 48 hours intravenous abciximab, and the other half placebo input. The study tested in the first month of abciximab reduced the incidence of heart attack or death opportunities. Not used abciximab in patients treated with 8% incidence or death, and the importation of the drug 24 hours and 48 hours respectively with 8.2 percent and 9.6 percent incidence.
The study of the main members, Yilacimashi University Hospital Rotterdam, the Netherlands (Erasmus University Hospital) medical professor Dr. Maarten Simoons said, "it has not shown any benefits for patients." At the same time, each have about 2% of The patients need to lift artery embolization. Some researchers hope that the drug will enable patients to avoid surgical treatment or angioplasty. Simoons said, "Some of us believe that this is feasible and all of the data support this."
Simoons said, the study found no effect of abciximab may be good because it is the amount has not yet generated significant difference to the extent of, or the timing of the drug application too late. Abciximab usually in the preoperative and intraoperative application of 12 hours. Mount Sinai School of Medicine, New York (Mount Sinai School of Medicine), Professor Michael Farkouh, he said, the drug can still help in a matter of hours, not conducted artery surgery in patients with heart disease. But he added that, to some extent, the study results did not surprise people. "We have always maintained that these drugs is to interventional therapy in patients with the best choice," he said, "That's all the evidence."
Abstract: The study found that a abciximab called on the stability of the anticoagulant heart attack and reduce its mortality effect has been disappointing.
Amsterdam, The Netherlands (AP) study found, the doctor can help quickly stabilize heart attack, reduce the mortality or morbidity an anticoagulant is disappointing. This can be called the drug abciximab in patients with heart artery expansion of interventional treatment, such as angioplasty, to prevent condensation blood cell adhesion to save lives, so that these operations more safe and effective. Its people impressed by the results, which researchers hope it can be improved non-surgical treatment the prognosis of the patients. But researchers found that it did not have the slightest effect.
European Heart Association in a meeting held on Monday announced the discovery. In a 7800 case of a heart attack caused by severe chest pain patients in the international study, all patients had mild anticoagulant rapidly taking the role of aspirin and heparin, as a basis for treatment. These patients the risk of a heart attack is high because they have not been completely blocked artery embolization flow.
In addition to aspirin and blood dilution, half of patients in 24 or 48 hours intravenous abciximab, and the other half placebo input. The study tested in the first month of abciximab reduced the incidence of heart attack or death opportunities. Not used abciximab in patients treated with 8% incidence or death, and the importation of the drug 24 hours and 48 hours respectively with 8.2 percent and 9.6 percent incidence.
The study of the main members, Yilacimashi University Hospital Rotterdam, the Netherlands (Erasmus University Hospital) medical professor Dr. Maarten Simoons said, "it has not shown any benefits for patients." At the same time, each have about 2% of The patients need to lift artery embolization. Some researchers hope that the drug will enable patients to avoid surgical treatment or angioplasty. Simoons said, "Some of us believe that this is feasible and all of the data support this."
Simoons said, the study found no effect of abciximab may be good because it is the amount has not yet generated significant difference to the extent of, or the timing of the drug application too late. Abciximab usually in the preoperative and intraoperative application of 12 hours. Mount Sinai School of Medicine, New York (Mount Sinai School of Medicine), Professor Michael Farkouh, he said, the drug can still help in a matter of hours, not conducted artery surgery in patients with heart disease. But he added that, to some extent, the study results did not surprise people. "We have always maintained that these drugs is to interventional therapy in patients with the best choice," he said, "That's all the evidence."